logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9266941 B1

PDFFull Text
Date of Patent:
Feb. 23, 2016

Filed:

May. 05, 2015

Apolipoprotein aiv as an antidiabetic peptide

Applicant:

University of Cincinnati, Cincinnati, OH (US);

Inventors:

Patrick Tso, Cincinnati, OH (US);

Sean Davidson, Cincinnati, OH (US);

Stephen Woods, Cincinnati, OH (US);

Fei Wang, Cincinnati, OH (US);

Assignee:

University of Cincinnati, Cincinnati, OH (US);

Attorneys:

McCarter & English, LLP

Steven G. Davis

Mei Bai

Primary Examiner:

James H Alstrum Acevedo

Assistant Examiner:

Thea D'Ambrosio

Int. Cl.
CPC ...
C07K 1/00 (2006.01); C07K 14/00 (2006.01); C07K 16/00 (2006.01); C07K 17/00 (2006.01); C09H 1/04 (2006.01); A61K 38/14 (2006.01); A61K 38/16 (2006.01); C07K 14/775 (2006.01); A61K 38/00 (2006.01); A61K 38/28 (2006.01); A61K 38/22 (2006.01); A61K 39/00 (2006.01); C07K 14/47 (2006.01); A61K 38/17 (2006.01); C07K 14/655 (2006.01); C07K 14/605 (2006.01); C07K 9/00 (2006.01); A61K 38/26 (2006.01);
U.S. Cl.
CPC ...
C07K 14/775 (2013.01); A61K 38/00 (2013.01); A61K 38/17 (2013.01); A61K 38/177 (2013.01); A61K 38/1709 (2013.01); A61K 38/22 (2013.01); A61K 38/26 (2013.01); A61K 38/28 (2013.01); A61K 39/00 (2013.01); C07K 9/005 (2013.01); C07K 9/008 (2013.01); C07K 14/47 (2013.01); C07K 14/605 (2013.01); C07K 14/6555 (2013.01);
Abstract

Methods for treating type two diabetes mellitus in a subject in need thereof and pharmaceutical compositions for the treatment of type two diabetes mellitus are disclosed. The methods include administering an effective amount of apolipoprotein A-IV to the subject. The pharmaceutical composition includes apolipoprotein A-IV formulated for administration to a subject for the treatment of type two diabetes mellitus. Also disclosed are methods for substantially restoring glucose tolerance in a subject in need thereof to a normal level and methods for lowering blood glucose levels in a subject in need thereof.

Find Patent Forward Citations

Loading…